Trial Profile
Single Arm, Multicentre Study of Carfilzomib in Combination With Thalidomide and Dexamethasone (CaTD) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms ALLG MM18
- 08 Dec 2020 Primary endpoint Progression free survival (PFS), has been met as per results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2020 Status changed from recruiting to active, no longer recruiting as per results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology